1
|
Larbre V, Romain-Scelle N, Reymond P, Ladjouzi Y, Herledan C, Caffin AG, Baudouin A, Maire M, Maucort-Boulch D, Ranchon F, Rioufol C. Cancer outpatients during the COVID-19 pandemic: what Oncoral has to teach us about medical drug use and the perception of telemedicine. J Cancer Res Clin Oncol 2023; 149:13301-13310. [PMID: 37482585 DOI: 10.1007/s00432-023-04971-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 06/03/2023] [Indexed: 07/25/2023]
Abstract
PURPOSE The COVID-19 pandemic has disrupted healthcare access and telemedicine has been widely deployed. The aim of this study is to assess the impact of this health crisis on treatment consumption and telemedicine development in outpatients treated by oral anti-cancer agents and followed by the Oncoral hospital/community multidisciplinary program where continuity care is maintained by a pharmacist/nurse pair. METHODS A prospective monocentric study was conducted among cancer patients who received Oncoral telephone follow-up during the 1st lockdown in France using a 56-item questionnaire which covered sociodemographic data, patient medication management, and telehealth. RESULTS 178 patients received Oncoral follow-up during the 1st lockdown and 67.4% responded to the questionnaire. During lockdown, 9.2% of patients took medication or CAM for fatigue, 6.7% for mood alteration, 10.8% for sleep disorder, 11.7% for stress and anxiety, and 12.5% to get more energy. Homeopathy consumption was triggered by the pandemic. Habits about getting drugs from the pharmacy changed significantly (p < 0.001), while other treatment habits did not. 83% of patients were satisfied by the telephone follow-up established, 69% would be in favor of repeating this in case of a new epidemic wave. Those most in favor of using telemedicine seemed to be the youngest (p < 0.001), with several dependent children (p < 0.007), high school degree or higher education (p = 0.023), and in work (p < 0.001). CONCLUSION Health system reorganization enables to limit the impact of the crisis on patients' drug use in oncology care. Telemedicine is a promising public health tool.
Collapse
Affiliation(s)
- V Larbre
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France
- Université Lyon 1-EA 3738, CICLY, Lyon, France
| | - N Romain-Scelle
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Pierre-Bénite, France
- Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, CNRS, UMR 5558, Villeurbanne, France
| | - P Reymond
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France
| | - Y Ladjouzi
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France
| | - C Herledan
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France
- Université Lyon 1-EA 3738, CICLY, Lyon, France
| | - A G Caffin
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France
| | - A Baudouin
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France
| | - M Maire
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France
| | - D Maucort-Boulch
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Pierre-Bénite, France
| | - F Ranchon
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France
- Université Lyon 1-EA 3738, CICLY, Lyon, France
| | - C Rioufol
- Hospices Civils de Lyon, Groupement Hospitalier Sud, Unité de Pharmacie Clinique Oncologique, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite Cedex, France.
- Université Lyon 1-EA 3738, CICLY, Lyon, France.
| |
Collapse
|
2
|
Szatmáry Z, Bardet SM, Mounier J, Janot K, Cortese J, Perrin ML, Couquet C, Deniau G, Hauquier F, Migneret R, Guenin E, Maire M, Michel JB, Forestier G, Le Flahec A, Leger-Bretou C, Mounayer C, Chaubet F, Rouchaud A. Fucoidan-coated coils improve healing in a rabbit elastase aneurysm model. J Neurointerv Surg 2023:jnis-2023-020596. [PMID: 37491380 DOI: 10.1136/jnis-2023-020596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 07/13/2023] [Indexed: 07/27/2023]
Abstract
BACKGROUND Recanalization of coiled aneurysms remains unresolved. To limit aneurysm recanalization after embolization with coils, we propose an innovative approach to optimize aneurysm healing using fucoidan-coated coils. OBJECTIVE To evaluate the short-term efficacy and long-term safety of the new coil system with conventional angiography, histology, and multiphoton microscopy for follow-up of fibrosis and neointima formation. METHODS We conducted a feasibility study on rabbit elastase-induced aneurysms. Embolization was carried out with bare platinum coils, fucoidan-coated coils, or dextran-coated coils. Aneurysms were controlled after 1 month by digital subtraction angiography (DSA). Aneurysm samples were collected and processed for histological analysis. Aneurysm healing and fibrosis were measured by quantifying collagen according to the histological healing score by combining standard light microscopy and multiphoton imaging. We divided 27 rabbits into three groups: bare platinum group, fucoidan group, and dextran group as controls. RESULTS Angiographic grading showed a trend toward less recanalization in the fucoidan group, although there were no significant differences among the three groups (P=0.21). Histological healing was significantly different according to the presence of more collagen in the neck area of aneurysms in the fucoidan group versus the bare platinum group (P=0.011), but not in the dextran group. Histological index was significantly better at the aneurysm neck in the fucoidan group than in the bare platinum group (P=0.004). Collagen organization index was also significantly better in the fucoidan group than in the bare platinum group (P=0.007). CONCLUSION This proof-of-concept study demonstrated the feasibility and efficacy of treatment with fucoidan-coated coils to improve aneurysm healing. The results in this rabbit in vivo model showed that fucoidan-coated coils have the potential to improve healing following endovascular treatment.
Collapse
Affiliation(s)
- Zoltán Szatmáry
- Department of Interventional Neuroradiology, Limoges University, Limoges, France
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, France
| | | | - Jérémy Mounier
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, France
| | - Kevin Janot
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, France
- Department of Interventional Neuroradiology, CHRU Tours CPU, Tours, France
| | - Jonathan Cortese
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, France
- Department of Interventional Neuroradiology-NEURI Brain Vascular Center APHP, Hospital Bicetre, Le Kremlin-Bicêtre, France
| | | | - Cladue Couquet
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, France
| | - Guy Deniau
- UMR CEA, CNRS 3685, NIMBE, LICSEN, Paris-Saclay University, Gif-sur-Yvette, France
| | - Fanny Hauquier
- UMR CEA, CNRS 3685, NIMBE, LICSEN, Paris-Saclay University, Gif-sur-Yvette, France
- Department of Chemistry and Health and Life Sciences, CNAM, Paris, France
| | - Rodolphe Migneret
- INSERM, UMRS 1148, LVTS, Paris, France
- Institut Galilée, Sorbonne North Paris University, Villetaneuse, France
| | - Erwann Guenin
- Laboratoire TIMR, Centre de Recherche Royallieu Rue du Dr Schweitzer - CS 6031960200, Compiègne, France
| | - Murielle Maire
- INSERM, UMRS 1148, LVTS, Paris, France
- Institut Galilée, Sorbonne North Paris University, Villetaneuse, France
| | | | - Géraud Forestier
- Department of Interventional Neuroradiology, Limoges University, Limoges, France
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, France
| | | | | | - Charbel Mounayer
- Department of Interventional Neuroradiology, Limoges University, Limoges, France
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, France
| | - Frederic Chaubet
- INSERM, UMRS 1148, LVTS, Paris, France
- Institut Galilée, Sorbonne North Paris University, Villetaneuse, France
| | - Aymeric Rouchaud
- Department of Interventional Neuroradiology, Limoges University, Limoges, France
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, France
| |
Collapse
|
3
|
Prely H, Herledan C, Caffin AG, Baudouin A, Larbre V, Maire M, Schwiertz V, Vantard N, Ranchon F, Rioufol C. Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases. J Cancer Res Clin Oncol 2021; 148:707-718. [PMID: 33914124 DOI: 10.1007/s00432-021-03645-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 04/16/2021] [Indexed: 11/29/2022]
Abstract
PURPOSE Due to polypharmacy and the rising popularity of complementary and alternative medicines (CAM), oncology patients are particularly at risk of drug-drug interactions (DDI) or herb-drug interactions (HDI). The aims of this study were to assess DDI and HDI in outpatients taking oral anticancer drug. METHOD All prescribed and non-prescribed medications, including CAM, were prospectively collected by hospital pharmacists during a structured interview with the patient. DDI and HDI were analyzed using four interaction software programs: Thériaque®, Drugs.com®, Hédrine, and Memorial Sloan Kettering Cancer Center (MSKCC) database. All detected interactions were characterized by severity, risk and action mechanism. The need for pharmaceutical intervention to modify drug use was determined on a case-by-case basis. RESULTS 294 patients were included, with a mean age of 67 years [55-79]. The median number of chronic drugs per patient was 8 [1-29] and 55% of patients used at least one CAM. At least 1 interaction was found for 267 patients (90.8%): 263 (89.4%) with DDI, 68 (23.1%) with HDI, and 64 (21.7%) with both DDI and HDI. Only 13% of the DDI were found in Thériaque® and Drugs.com® databases, and 125 (2.5%) were reported with similar level of risk on both databases. 104 HDI were identified with only 9.5% of the interactions found in both databases. 103 pharmaceutical interventions were performed, involving 61 patients (20.7%). CONCLUSION Potentially clinically relevant drug interaction were frequently identified in this study, showing that several databases and structured screening are required to detect more interactions and optimize medication safety.
Collapse
Affiliation(s)
- H Prely
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France
| | - C Herledan
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France.,Centre Pour l'Innovation en Cancérologie de Lyon, Université Lyon 1- EA 3738, Lyon, France
| | - A G Caffin
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France
| | - A Baudouin
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France
| | - V Larbre
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France.,Centre Pour l'Innovation en Cancérologie de Lyon, Université Lyon 1- EA 3738, Lyon, France
| | - M Maire
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France
| | - V Schwiertz
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France
| | - N Vantard
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France
| | - F Ranchon
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France.,Centre Pour l'Innovation en Cancérologie de Lyon, Université Lyon 1- EA 3738, Lyon, France
| | - C Rioufol
- Clinical Oncology Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Sud, Pharmacy, 165 Chemin du Grand Revoyet, 69495, Pierre Bénite, France. .,Centre Pour l'Innovation en Cancérologie de Lyon, Université Lyon 1- EA 3738, Lyon, France.
| |
Collapse
|
4
|
Arce P, Bolst D, Bordage MC, Brown JMC, Cirrone P, Cortés-Giraldo MA, Cutajar D, Cuttone G, Desorgher L, Dondero P, Dotti A, Faddegon B, Fedon C, Guatelli S, Incerti S, Ivanchenko V, Konstantinov D, Kyriakou I, Latyshev G, Le A, Mancini-Terracciano C, Maire M, Mantero A, Novak M, Omachi C, Pandola L, Perales A, Perrot Y, Petringa G, Quesada JM, Ramos-Méndez J, Romano F, Rosenfeld AB, Sarmiento LG, Sakata D, Sasaki T, Sechopoulos I, Simpson EC, Toshito T, Wright DH. Report on G4-Med, a Geant4 benchmarking system for medical physics applications developed by the Geant4 Medical Simulation Benchmarking Group. Med Phys 2021; 48:19-56. [PMID: 32392626 PMCID: PMC8054528 DOI: 10.1002/mp.14226] [Citation(s) in RCA: 63] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 04/26/2020] [Accepted: 04/30/2020] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND Geant4 is a Monte Carlo code extensively used in medical physics for a wide range of applications, such as dosimetry, micro- and nanodosimetry, imaging, radiation protection, and nuclear medicine. Geant4 is continuously evolving, so it is crucial to have a system that benchmarks this Monte Carlo code for medical physics against reference data and to perform regression testing. AIMS To respond to these needs, we developed G4-Med, a benchmarking and regression testing system of Geant4 for medical physics. MATERIALS AND METHODS G4-Med currently includes 18 tests. They range from the benchmarking of fundamental physics quantities to the testing of Monte Carlo simulation setups typical of medical physics applications. Both electromagnetic and hadronic physics processes and models within the prebuilt Geant4 physics lists are tested. The tests included in G4-Med are executed on the CERN computing infrastructure via the use of the geant-val web application, developed at CERN for Geant4 testing. The physical observables can be compared to reference data for benchmarking and to results of previous Geant4 versions for regression testing purposes. RESULTS This paper describes the tests included in G4-Med and shows the results derived from the benchmarking of Geant4 10.5 against reference data. DISCUSSION Our results indicate that the Geant4 electromagnetic physics constructor G4EmStandardPhysics_option4 gives a good agreement with the reference data for all the tests. The QGSP_BIC_HP physics list provided an overall adequate description of the physics involved in hadron therapy, including proton and carbon ion therapy. New tests should be included in the next stage of the project to extend the benchmarking to other physical quantities and application scenarios of interest for medical physics. CONCLUSION The results presented and discussed in this paper will aid users in tailoring physics lists to their particular application.
Collapse
Affiliation(s)
| | - D Bolst
- Centre For Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | - M-C Bordage
- CRCT (INSERM and Paul Sabatier University), Toulouse, France
| | - J M C Brown
- Department of Radiation Science and Technology, Delft University of Technology, Delft, The Netherlands
| | | | | | - D Cutajar
- Centre For Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | | | - L Desorgher
- Institute of Radiation Physics (IRA), Lausanne University Hospital, Lausanne, Switzerland
| | | | - A Dotti
- SLAC National Accelerator Laboratory, Stanford, CA, USA
| | - B Faddegon
- University of California, San Francisco, CA, USA
| | - C Fedon
- Radboud University Medical Center, Nijmegen, The Netherlands
| | - S Guatelli
- Centre For Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | - S Incerti
- Université de Bordeaux, CNRS/IN2P3, UMR5797, Centre d'Études Nucléaires de Bordeaux Gradignan, Gradignan, France
| | - V Ivanchenko
- Tomsk State University, Tomsk, Russian Federation
- CERN, Geneva, Switzerland
| | - D Konstantinov
- NRC "Kurchatov Institute" - IHEP, Protvino, Russian Federation
| | - I Kyriakou
- Medical Physics Laboratory, University of Ioannina, Ioannina, Greece
| | - G Latyshev
- NRC "Kurchatov Institute" - IHEP, Protvino, Russian Federation
| | - A Le
- Centre For Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | | | | | | | | | - C Omachi
- Nagoya Proton Therapy Center, Nagoya, Japan
| | | | - A Perales
- Medical Physics Department of Clínica Universidad de Navarra, Pamplona, Spain
| | - Y Perrot
- IRSN, Fontenay-aux-Roses, France
| | | | | | | | - F Romano
- INFN Catania Section, Catania, Italy
- Medical Physics Department, National Physical Laboratory, Teddington, UK
| | - A B Rosenfeld
- Centre For Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | | | - D Sakata
- Centre For Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | | | - I Sechopoulos
- Radboud University Medical Center, Nijmegen, The Netherlands
- Dutch Expert Center for Screening (LRCB), Nijmegen, The Netherlands
| | - E C Simpson
- Department of Nuclear Physics, Research School of Physics, Australian National University, Canberra, Australia
| | - T Toshito
- Nagoya Proton Therapy Center, Nagoya, Japan
| | - D H Wright
- SLAC National Accelerator Laboratory, Stanford, CA, USA
| |
Collapse
|
5
|
Brouillaud-Delattre A, Maire M, Collette C, Mattei C, Lahellec C. Predictive Microbiology of Dairy Products: Influence of Biological Factors Affecting Growth of Listeria monocytogenes. J AOAC Int 2020. [DOI: 10.1093/jaoac/80.4.913] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
The growth potential of Listeria monocytogenes was evaluated at low temperature in sterilized milk and raw dairy products. Sterilized and raw milk were inoculated with different strains of L. monocytogenes in 2 physiological states and at various contamination levels. Raw cheese was naturally contaminated with Listeria spp. The results suggest that some biological factors influence the growth capacity of L. monocytogenes in dairy products. Significant strain effect was observed at low temperature whatever the growth medium. By contrast, no inoculum effect was observed in the 3 dairy products. In raw matrixes, growth of L. monocytogenes was influenced greatly by bacterial interactions and physiological state of inoculum cells.
Collapse
Affiliation(s)
| | | | | | - Cesar Mattei
- CNEVA-Paris, 43 Rue de Dantzig, 75 015 Paris, France
| | | |
Collapse
|
6
|
Marinval N, Morenc M, Labour M, Samotus A, Mzyk A, Ollivier V, Maire M, Jesse K, Bassand K, Niemiec-Cyganek A, Haddad O, Jacob M, Chaubet F, Charnaux N, Wilczek P, Hlawaty H. Fucoidan/VEGF-based surface modification of decellularized pulmonary heart valve improves the antithrombotic and re-endothelialization potential of bioprostheses. Biomaterials 2018; 172:14-29. [DOI: 10.1016/j.biomaterials.2018.01.054] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Revised: 01/29/2018] [Accepted: 01/29/2018] [Indexed: 12/02/2022]
|
7
|
Ghebouli R, Loyau S, Maire M, Saboural P, Collet JP, Jandrot-Perrus M, Letourneur D, Chaubet F, Michel JB. Amino-Fucoidan as a Vector for rtPA-Induced Fibrinolysis in Experimental Thrombotic Events. Thromb Haemost 2018; 118:42-53. [DOI: 10.1160/th17-02-0132] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
AbstractAcute ischaemic stroke, myocardial infarction and pulmonary embolism are the main causes of mortality and morbidity worldwide. Thrombolysis by intravenous injection of recombinant tissue plasminogen activator (rtPA) remains the most common non-interventional treatment to recanalize occluded vessels. However, this procedure is limited by significant drawbacks, including high doses and bleeding complications. Recent studies showed that fucoidan targets the intraluminal thrombus in vivo. We have developed a chimaera covalently linking fucoidan, able to target platelets within the thrombus, to dilysine, able to non-covalently bind rtPA. We hypothesize that this construct should vectorize rtPA to the thrombus, thus increasing its fibrinolytic efficacy and avoiding its deleterious effects. In vitro, rtPA mixed to dilysine fucoidan (DLF) shows a greater fibrinolytic effect than rtPA alone, both on platelet-rich thrombus and in whole blood. In vivo, occluded mesenteric vessels, carotid artery and vena cava were more efficiently recanalized by DLF complexed to rtPA than by rtPA alone. This study thus provides evidence that DLF may be a promising therapeutic tool to fight against acute thrombosis by enhancing rtPA fibrinolytic efficiency.
Collapse
|
8
|
Nghia NNTN, Tinet E, Ettori D, Beilvert A, Pavon-Djavid G, Maire M, Ou P, Tualle JM, Chaubet F. Gadolinium/terbium hybrid macromolecular complexes for bimodal imaging of atherothrombosis. J Biomed Opt 2017; 22:76004. [PMID: 28697231 DOI: 10.1117/1.jbo.22.7.076004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 06/15/2017] [Indexed: 06/07/2023]
Abstract
We developed a fluorescence imaging microscope system intended for the localization within artery slices of a gadolinium-based macromolecular biospecific magnetic resonance (MR) contrast agent used for the visualization of atherothrombosis. As the contrast agent is not initially fluorescent, we substitute some gadolinium ions for terbium ions to make them fluorescent while preserving their chemical characteristics. A long fluorescence emission time constant enables us to have a suitable signal-to-noise ratio, despite a low intensity, using pulsed illumination and time-gated imaging. Images of rat arteries show that the contrast agent is indeed localized on the specific regions of the tissues. We currently have a tool that allows us to understand and optimize the MR contrast agent.
Collapse
Affiliation(s)
- Nguy N Tr Ng Nghia
- University Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laser Physics Laboratory, CNRS UMR 7538, Villetaneuse, FrancebUniversity Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laboratory for Vascular Translational Science, INSERM U1148, Villetaneuse, France
| | - Eric Tinet
- University Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laser Physics Laboratory, CNRS UMR 7538, Villetaneuse, France
| | - Dominique Ettori
- University Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laser Physics Laboratory, CNRS UMR 7538, Villetaneuse, France
| | - Anne Beilvert
- University Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laboratory for Vascular Translational Science, INSERM U1148, Villetaneuse, France
| | - Graciela Pavon-Djavid
- University Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laboratory for Vascular Translational Science, INSERM U1148, Villetaneuse, France
| | - Murielle Maire
- University Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laboratory for Vascular Translational Science, INSERM U1148, Villetaneuse, France
| | - Phalla Ou
- University Paris-Diderot, CHU X. Bichat, University Sorbonne Paris-Cité, Laboratory for Vascular Translational Science, INSERM U1148, Paris, FrancedHôpital Bichat, AP-HP, Paris, France
| | - Jean-Michel Tualle
- University Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laser Physics Laboratory, CNRS UMR 7538, Villetaneuse, France
| | - Frédéric Chaubet
- University Paris 13, Institut Galilée, University Sorbonne Paris-Cité, Laboratory for Vascular Translational Science, INSERM U1148, Villetaneuse, France
| |
Collapse
|
9
|
Li B, Juenet M, Aid-Launais R, Maire M, Ollivier V, Letourneur D, Chauvierre C. Thrombosis Treatment: Development of Polymer Microcapsules Functionalized with Fucoidan to Target P-Selectin Overexpressed in Cardiovascular Diseases (Adv. Healthcare Mater. 4/2017). Adv Healthc Mater 2017. [DOI: 10.1002/adhm.201770021] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Bo Li
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Maya Juenet
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Rachida Aid-Launais
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Murielle Maire
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Véronique Ollivier
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Didier Letourneur
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Cédric Chauvierre
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| |
Collapse
|
10
|
Li B, Juenet M, Aid-Launais R, Maire M, Ollivier V, Letourneur D, Chauvierre C. Development of Polymer Microcapsules Functionalized with Fucoidan to Target P-Selectin Overexpressed in Cardiovascular Diseases. Adv Healthc Mater 2017; 6. [PMID: 27943662 DOI: 10.1002/adhm.201601200] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Indexed: 12/17/2022]
Abstract
New tools for molecular imaging and targeted therapy for cardiovascular diseases are still required. Herein, biodegradable microcapsules (MCs) made of polycyanoacrylate and polysaccharide and functionalized with fucoidan (Fuco-MCs) are designed as new carriers to target arterial thrombi overexpressing P-selectin. Physicochemical characterizations demonstrated that microcapsules have a core-shell structure and that fucoidan is present onto the surface of Fuco-MCs. Furthermore, their sizes range from 2 to 6 µm and they are stable on storage over 30 d at 4 °C. Flow cytometry experiments evidenced the binding of Fuco-MCs for human activated platelets as compared to MCs (mean fluorescence intensity: 12 008 vs. 9, p < 0.001) and its absence for nonactivated platelets (432). An in vitro flow adhesion assay showed high specific binding efficiency of Fuco-MCs to P-selectin and to activated platelet aggregates under arterial shear stress conditions. Moreover, both types of microcapsules reveal excellent compatibility with 3T3 cells in cytotoxicity assay. One hour after intravenous injection of microcapsules, histological analysis revealed that Fuco-MCs are localized in the rat abdominal aortic aneurysm thrombotic wall and that the binding in the healthy aorta is low. In conclusion, these microcapsules appear as promising carriers for targeting of tissues characterized by P-selectin overexpression and for their molecular imaging or treatment.
Collapse
Affiliation(s)
- Bo Li
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Maya Juenet
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Rachida Aid-Launais
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Murielle Maire
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Véronique Ollivier
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Didier Letourneur
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| | - Cédric Chauvierre
- INSERM; U1148; Laboratory for Vascular Translational Science; CHU X. Bichat; Paris Diderot University; 46 rue H. Huchard 75018 Paris France
- Institut Galilée; Paris 13 University; 99 av JB Clément 93430 Villetaneuse France
| |
Collapse
|
11
|
Marinval N, Saboural P, Haddad O, Maire M, Bassand K, Geinguenaud F, Djaker N, Ben Akrout K, Lamy de la Chapelle M, Robert R, Oudar O, Guyot E, Laguillier-Morizot C, Sutton A, Chauvierre C, Chaubet F, Charnaux N, Hlawaty H. Identification of a Pro-Angiogenic Potential and Cellular Uptake Mechanism of a LMW Highly Sulfated Fraction of Fucoidan from Ascophyllum nodosum. Mar Drugs 2016; 14:E185. [PMID: 27763505 PMCID: PMC5082333 DOI: 10.3390/md14100185] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 09/28/2016] [Accepted: 10/10/2016] [Indexed: 02/04/2023] Open
Abstract
Herein we investigate the structure/function relationships of fucoidans from Ascophyllum nodosum to analyze their pro-angiogenic effect and cellular uptake in native and glycosaminoglycan-free (GAG-free) human endothelial cells (HUVECs). Fucoidans are marine sulfated polysaccharides, which act as glycosaminoglycans mimetics. We hypothesized that the size and sulfation rate of fucoidans influence their ability to induce pro-angiogenic processes independently of GAGs. We collected two fractions of fucoidans, Low and Medium Molecular Weight Fucoidan (LMWF and MMWF, respectively) by size exclusion chromatography and characterized their composition (sulfate, fucose and uronic acid) by colorimetric measurement and Raman and FT-IR spectroscopy. The high affinities of fractionated fucoidans to heparin binding proteins were confirmed by Surface Plasmon Resonance. We evidenced that LMWF has a higher pro-angiogenic (2D-angiogenesis on Matrigel) and pro-migratory (Boyden chamber) potential on HUVECs, compared to MMWF. Interestingly, in a GAG-free HUVECs model, LMWF kept a pro-angiogenic potential. Finally, to evaluate the association of LMWF-induced biological effects and its cellular uptake, we analyzed by confocal microscopy the GAGs involvement in the internalization of a fluorescent LMWF. The fluorescent LMWF was mainly internalized through HUVEC clathrin-dependent endocytosis in which GAGs were partially involved. In conclusion, a better characterization of the relationships between the fucoidan structure and its pro-angiogenic potential in GAG-free endothelial cells was required to identify an adapted fucoidan to enhance vascular repair in ischemia.
Collapse
Affiliation(s)
- Nicolas Marinval
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Pierre Saboural
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Oualid Haddad
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Murielle Maire
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Kevin Bassand
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Frederic Geinguenaud
- Laboratoire CSPBAT, CNRS UMR 7244, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny F-93017, France.
| | - Nadia Djaker
- Laboratoire CSPBAT, CNRS UMR 7244, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny F-93017, France.
| | - Khadija Ben Akrout
- Laboratoire CSPBAT, CNRS UMR 7244, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny F-93017, France.
| | - Marc Lamy de la Chapelle
- Laboratoire CSPBAT, CNRS UMR 7244, UFR SMBH, Université Paris 13, Sorbonne Paris Cité, Bobigny F-93017, France.
| | - Romain Robert
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Olivier Oudar
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Erwan Guyot
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
- Laboratoire de Biochimie, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris, Bondy 93140, France.
| | - Christelle Laguillier-Morizot
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
- Laboratoire de Biochimie, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris, Bondy 93140, France.
| | - Angela Sutton
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
- Laboratoire de Biochimie, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris, Bondy 93140, France.
| | - Cedric Chauvierre
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Frederic Chaubet
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| | - Nathalie Charnaux
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
- Laboratoire de Biochimie, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris, Bondy 93140, France.
| | - Hanna Hlawaty
- Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Paris 75018, France.
| |
Collapse
|
12
|
Apostolakis J, Asai M, Bagulya A, Brown JMC, Burkhardt H, Chikuma N, Cortes-Giraldo MA, Elles S, Grichine V, Guatelli S, Incerti S, Ivanchenko VN, Jacquemier J, Kadri O, Maire M, Pandola L, Sawkey D, Toshito T, Urban L, Yamashita T. Progress in Geant4 Electromagnetic Physics Modelling and Validation. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/1742-6596/664/7/072021] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
13
|
Marinval N, Saboural P, Haddad O, Maire M, Letourneur D, Charnaux N, Hlawaty H. 0024 : Angiogenesis potentialized by highly sulfated fucoidan: role of the chemokines and the proteoglycans. Archives of Cardiovascular Diseases Supplements 2015. [DOI: 10.1016/s1878-6480(15)30050-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Saboural P, Chaubet F, Rouzet F, Al-Shoukr F, Ben Azzouna R, Bouchemal N, Picton L, Louedec L, Maire M, Rolland L, Potier G, Le Guludec D, Letourneur D, Chauvierre C. Purification of a low molecular weight fucoidan for SPECT molecular imaging of myocardial infarction. Mar Drugs 2014; 12:4851-67. [PMID: 25251032 PMCID: PMC4178488 DOI: 10.3390/md12094851] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 09/05/2014] [Accepted: 09/09/2014] [Indexed: 12/19/2022] Open
Abstract
Fucoidans constitute a large family of sulfated polysaccharides with several biochemical properties. A commercial fucoidan from brown algae, containing low molecular weight polysaccharidic species constituted of l-fucose, uronic acids and sulfate groups, was simply treated here with calcium acetate solution. This treatment led to a purified fraction with a yield of 45%. The physicochemical characterizations of the purified fucoidan using colorimetric assay, MALLS, dRI, FT-IR, NMR, exhibited molecular weight distributions and chemical profiles similar for both fucoidans whereas the sulfate and l-fucose contents increased by 16% and 71%, respectively. The biodistribution study in rat of both compounds labeled with 99mTc evidenced a predominant renal elimination of the purified fucoidan, but the crude fucoidan was mainly retained in liver and spleen. In rat myocardial ischemia-reperfusion, we then demonstrated the better efficiency of the purified fucoidan. This purified sulfated polysaccharide appears promising for the development of molecular imaging in acute coronary syndrome.
Collapse
Affiliation(s)
- Pierre Saboural
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Galilée Institute, Paris 13 University, Sorbonne Paris Cité, F-93430, Villetaneuse, France
| | - Frédéric Chaubet
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Galilée Institute, Paris 13 University, Sorbonne Paris Cité, F-93430, Villetaneuse, France
| | - Francois Rouzet
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Multimodal Imaging Research Federation (FRIM), Paris Diderot University, F-75877, Paris, France
- Nuclear Medicine Department, Bichat-Claude Bernard Hospital, AP-HP, F-75877, Paris, France
| | - Faisal Al-Shoukr
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Multimodal Imaging Research Federation (FRIM), Paris Diderot University, F-75877, Paris, France
- Nuclear Medicine Department, Bichat-Claude Bernard Hospital, AP-HP, F-75877, Paris, France
| | - Rana Ben Azzouna
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Galilée Institute, Paris 13 University, Sorbonne Paris Cité, F-93430, Villetaneuse, France
- Multimodal Imaging Research Federation (FRIM), Paris Diderot University, F-75877, Paris, France
- Nuclear Medicine Department, Bichat-Claude Bernard Hospital, AP-HP, F-75877, Paris, France
| | - Nadia Bouchemal
- Laboratory CSPBAT, Paris 13 University, Sorbonne Paris Cité, CNRS UMR 7244, SBMB team, F-93017, Bobigny, France; E-Mail:
| | - Luc Picton
- Laboratory of Polymers Biopolymers Surfaces, Normandie University, Rouen University, F-76821, Mont Saint Aignan, France; E-Mail:
- Laboratory of Polymers Biopolymers Surfaces, CNRS, UMR 6270 and FR3038, F-76821, Mont Saint Aignan, France
| | - Liliane Louedec
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
| | - Murielle Maire
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Galilée Institute, Paris 13 University, Sorbonne Paris Cité, F-93430, Villetaneuse, France
| | - Lydia Rolland
- Algues & Mer, Kernigou, F-29242, Ouessant, France; E-Mails: (L.R.); (G.P.)
| | - Guy Potier
- Algues & Mer, Kernigou, F-29242, Ouessant, France; E-Mails: (L.R.); (G.P.)
| | - Dominique Le Guludec
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Multimodal Imaging Research Federation (FRIM), Paris Diderot University, F-75877, Paris, France
- Nuclear Medicine Department, Bichat-Claude Bernard Hospital, AP-HP, F-75877, Paris, France
| | - Didier Letourneur
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Galilée Institute, Paris 13 University, Sorbonne Paris Cité, F-93430, Villetaneuse, France
| | - Cédric Chauvierre
- Inserm, U1148, LVTS, Paris Diderot University, Bichat-Claude Bernard Hospital, F-75877, Paris, France; E-Mails: (P.S.); (F.C.); (F.R.); (F.A.-S.); (R.B.A.); (L.L.); (M.M.); (D.L.G.); (D.L.)
- Galilée Institute, Paris 13 University, Sorbonne Paris Cité, F-93430, Villetaneuse, France
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +33-1-4025-7538; Fax: +33-1-4025-8602
| |
Collapse
|
15
|
Suzuki M, Bachelet-Violette L, Rouzet F, Beilvert A, Autret G, Maire M, Menager C, Louedec L, Choqueux C, Saboural P, Haddad O, Chauvierre C, Chaubet F, Michel JB, Serfaty JM, Letourneur D. Ultrasmall superparamagnetic iron oxide nanoparticles coated with fucoidan for molecular MRI of intraluminal thrombus. Nanomedicine (Lond) 2014; 10:73-87. [PMID: 24960075 DOI: 10.2217/nnm.14.51] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
AIM We have designed ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles associated with fucoidan (USPOI-FUCO), a natural sulfated polysaccharide with high affinity for activated platelets, to visualize by MRI arterial thrombi. MATERIALS & METHODS USPIOs were prepared and sizes, zeta-potentials and relaxivities were measured. Elastase perfusion in the infrarenal aorta of Wistar rats induced intraluminal thrombus. They were scanned on 4.7 T MRI before and after injection of USPIO-FUCO or USPIO coated with anionic dextran. RESULTS Surface plasmon resonance evidenced that fucoidan and USPIO-FUCO bind in vitro to immobilized P-selectin. All intraluminal hyposignals detected by MRI after injection of USPIO-FUCO on animals (13 out of 13) were correlated by histology with thrombi, whereas none could be identified with control USPIOs (0 out of 7). No signal was seen in absence of thrombus. Thrombi by MRI were correlated with P-selectin immunostaining and USPIO detection by electron microscopy. CONCLUSION In vivo thrombi can thus be evidenced by MRI with USPIO-FUCO.
Collapse
Affiliation(s)
- Michimasa Suzuki
- French Institute of Health & Medical Research (Inserm) U1148, Laboratory for Vascular Translational Science, CHU X Bichat, University Paris 7, 46 rue H Huchard, F-75877, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Bachelet-Violette L, Silva AKA, Maire M, Michel A, Brinza O, Ou P, Ollivier V, Nicoletti A, Wilhelm C, Letourneur D, Ménager C, Chaubet F. Strong and specific interaction of ultra small superparamagnetic iron oxide nanoparticles and human activated platelets mediated by fucoidan coating. RSC Adv 2014. [DOI: 10.1039/c3ra46757k] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
17
|
Maire M, Rega B, Cuvelier ME, Soto P, Giampaoli P. Lipid oxidation in baked products: Impact of formula and process on the generation of volatile compounds. Food Chem 2013; 141:3510-8. [DOI: 10.1016/j.foodchem.2013.06.039] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Revised: 02/13/2013] [Accepted: 06/10/2013] [Indexed: 10/26/2022]
|
18
|
Allison J, Apostolakis J, Bagulya A, Champion C, Elles S, Garay F, Grichine V, Howard A, Incerti S, Ivanchenko V, Jacquemier J, Maire M, Mantero A, Nieminen P, Pandola L, Santin G, Sawkey D, Schälicke A, Urban L. Geant4 electromagnetic physics for high statistic simulation of LHC experiments. ACTA ACUST UNITED AC 2012. [DOI: 10.1088/1742-6596/396/2/022013] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
19
|
Maire M, Jaquet N, Rast C, Vasseur P. Cell transformation assays for the evaluation of in vitro carcinogenesis of chemicals substances and pollutants. Toxicol Lett 2011. [DOI: 10.1016/j.toxlet.2011.05.706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
|
21
|
Apostolakis J, Bagulya A, Elles S, Ivanchenko VN, Jacquemier J, Maire M, Toshito T, Urban L. Validation and verification of Geant4 standard electromagnetic physics. ACTA ACUST UNITED AC 2010. [DOI: 10.1088/1742-6596/219/3/032044] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
22
|
Apostolakis J, Bagulya A, Elles S, Ivanchenko VN, Kadri O, Maire M, Urban L. The performance of the geant4 standard EM package for LHC and other applications. ACTA ACUST UNITED AC 2008. [DOI: 10.1088/1742-6596/119/3/032004] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
23
|
|
24
|
De Buyser ML, Dufour B, Maire M, Lafarge V. Implication of milk and milk products in food-borne diseases in France and in different industrialised countries. Int J Food Microbiol 2001; 67:1-17. [PMID: 11482557 DOI: 10.1016/s0168-1605(01)00443-3] [Citation(s) in RCA: 334] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
A study was carried out to estimate the proportion of diseases due to milk and milk products among food-borne diseases recorded in France and in other countries since 1980. Particular attention was given to whether the milk involved was heat-treated or not. Four etiologic agents were considered: Salmonella spp., Staphylococcus aureus, Listeria monocytogenes, and pathogenic Escherichia coli. An overview of food-borne disease annual reports from seven countries indicated that milk and milk products were implicated in 1-5% of the total bacterial outbreaks; however, details about the type of product and milk involved were usually not provided. When considering 60 outbreaks and four single cases described in the literature and implicating milk and milk products, confirmed or suspected food vehicles were distributed as follows: milk, 39.1%, cheese, 53.1%, other milk products, 7.8%. Overall, 32.8% of the food vehicles were made from pasteurised milk; 37.5% from raw milk; 10.9% from milk stated as "unpasteurised"; and 18.8% from unspecified milk. Salmonella spp. were responsible for 29 outbreaks, L. monocytogenes for 10 outbreaks and four well-documented single cases, pathogenic E. coli for 11 outbreaks, and S. aureus for 10 outbreaks. Analysis of unpublished data about food-borne disease outbreaks, listeriosis excluded, collected by the coordinator of the French surveillance system from 1992 to 1997, revealed 69 documented outbreaks for which milk and milk products were confirmed as the vehicle by the isolation of the etiologic agent. The food vehicles were distributed as follows: milk, 10%; cheese, 87%; others, 3%. UHT milk accounted for 1.5%, raw milk and raw milk products for 48%, and milk and milk products from unspecified milk for 50.5% of the 69 outbreaks. S. aureus was by far the most frequent pathogen associated with these outbreaks (85.5% of the outbreaks), followed by Salmonella (10.1%). This study demonstrates the limitations of the surveillance systems and the difficulties in estimating the contribution of milk and milk products to food-borne diseases. In particular, it was not possible to find out in many outbreaks what heat treatment, if any, the milk had undergone.
Collapse
Affiliation(s)
- M L De Buyser
- Agence Francaise de Sécurité Sanitaire des Aliments (AFSSA), Laboratoire d'Etudes et de Recherches sur l'Hygiène et la Qualité des Aliments, Maisons-Alfort, France.
| | | | | | | |
Collapse
|
25
|
Brouillaud-Delattre A, Maire M, Collette C, Mattei C, Lahellec C. Predictive microbiology of dairy products: influence of biological factors affecting growth of Listeria monocytogenes. J AOAC Int 1997; 80:913-9. [PMID: 9241852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The growth potential of Listeria monocytogenes was evaluated at low temperature in sterilized milk and raw dairy products. Sterilized and raw milk were inoculated with different strains of L. monocytogenes in 2 physiological states and at various contamination levels. Raw cheese was naturally contaminated with Listeria spp. The results suggest that some biological factors influence the growth capacity of L monocytogenes in dairy products. Significant strain effect was observed at low temperature whatever the growth medium. By contrast, no inoculum effect was observed in the 3 dairy products. In raw matrixes, growth of L. monocytogenes was influenced greatly by bacterial interactions and physiological state of inoculum cells.
Collapse
|
26
|
Aurenche P, Bopp FW, Capella A, Kwiecinski J, Maire M, Ranft J. Multiparticle production in a two-component dual parton model. Phys Rev D Part Fields 1992; 45:92-105. [PMID: 10014194 DOI: 10.1103/physrevd.45.92] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
27
|
Maire M. [A French dental team for Chad]. Chir Dent Fr 1984; 54:33-5. [PMID: 6598124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
28
|
Celada A, Aguado MT, Maire M, Ortega F, Magallon M, Martin-Villar J, Lambert PH. Effect of circulating immune complexes on transfusional therapy in patients with hemophilia or von Willebrand's disease. Transfusion 1984; 24:46-52. [PMID: 6420954 DOI: 10.1046/j.1537-2995.1984.24184122561.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Circulating immune complexes were examined in patients with hemophilia or von Willebrand's disease in order to determine the immediate or long-term side effects after transfusion. The conglutinin binding assay which allows quantitation of C3bi-bearing immune complexes was used for 82 patients with hemophilia A. Immune complexes were detected in 37 (45%) of these cases prior to transfusion. Immune complexes also were detected in four of 11 patients with hemophilia A and factor VIII inhibitors, in five of 11 patients with hemophilia B, and in three of 10 patients with von Willebrand's disease. The levels of circulating immune complexes in 21 patients with hemophilia A and seven with von Willebrand's disease significantly increased 24 hours after concentrate or cryoprecipitate transfusions. Purified immune complexes from three patients with hemophilia A were shown to contain IgG, IgM, and complement components. No factor VIII coagulant or antigenic protein or fibrinogen was identified in the immune complexes using specific antisera. Side effects immediately after transfusion were not associated with immune complexes. The levels of factor VIII or IX after transfusion were not particularly decreased in relation to the presence of immune complexes. Finally, the presence of circulating immune complexes in the patients studied did not correlate with the number of transfusions, the units of concentrates injected, the presence of HBsAg or HbsAb, the levels of plasma aspartate transferase, or the presence of rheumatoid factor. Proteinuria was absent in all the patients studied.
Collapse
|
29
|
Chakrabarty AK, Maire M, Saha K, Lambert PH. Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Clin Exp Immunol 1983; 51:225-31. [PMID: 6340869 PMCID: PMC1536874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Immune complexes have been purified from sera of patients with lepromatous leprosy, using solid phase conglutinin and analysed by SDS-PAGE. Some of their components have been immunologically identified after electrophoretic blotting on nitrocellulose. First, immunoglobulins, complement components (C1q, C1s, C3) and CRP were found in IC. Secondly, one mycobacterial antigen of 67 kD was directly identified in IC while two other components (20 kD and 14.4 kD) of possible M. leprae origin were also found in IC. This study suggests that lepromatous patients develop a good antibody response against some M. leprae antigens (33 kD and 12 kD), which are rapidly eliminated from circulation, while other M. leprae antigens (e.g. 67 kD) can persist in relative antigen excess, within circulating IC.
Collapse
|
30
|
Maire M. [An hour with Prof. Jean Hamburger]. Chir Dent Fr 1981; 51:35-9. [PMID: 7032853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
31
|
Allkofer O, Aubert J, Bassompierre G, Becks K, Bertsch Y, Besson C, Best C, Böhm E, Botterill D, Brasse F, Broll C, Carr J, Charles B, Clifft R, Cobb J, Coignet G, Combley F, Crespo J, Dalpiaz P, Dalpiaz P, Dau W, Davies J, Declais Y, Dobinson R, Drees J, Edwards A, Edwards M, Favier J, Ferrero M, Field J, Flauger W, Gabathuler E, Gamet R, Gayler J, Ghez P, Gössling G, Haas J, Hahn U, Hamacher K, Hayman P, Henckes M, Jokisch H, Kadyk J, Korbel V, Maire M, Massonnet L, Melissinos A, Mohr W, Montgomery H, Moser K, Mount R, Moynot M, Norton P, Osborne A, Payre P, Peroni C, Pessard H, Pietrzyk U, Rith K, Rousseau M, Schlösser E, Schneegans M, Sloan T, Sproston M, Stockhausen W, Stier H, Thénard J, Thompson J, Urban L, Vivargent M, von Holtey G, Wahlen H, Watson E, White V, Williams D, Williams W, Wimpenny S. A large magnetic spectrometer system for high-energy muon physics. ACTA ACUST UNITED AC 1981. [DOI: 10.1016/0029-554x(81)90169-5] [Citation(s) in RCA: 105] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Maire M. [A mini-history of the dental press]. Chir Dent Fr 1979; 49:53-7. [PMID: 398248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
33
|
Maire M. [The gold of time. The Museum of Dentistry of the dental school of Lyon]. Chir Dent Fr 1979; 49:25-30. [PMID: 293249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
34
|
Maire M. [Death of Mao Tse Tung (or Mao Dze Dong)]. Chir Dent Fr 1976; 46:63. [PMID: 802697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
35
|
Rizzolo LJ, Maire M, Reynolds JA, Tanford C. Molecular weights and hydrophobicity of the polypeptide chain of sarcoplasmic reticulum calcium(II) adenosine triphosphatase and of its primary tryptic fragments. Biochemistry 1976; 15:3433-7. [PMID: 133715 DOI: 10.1021/bi00661a006] [Citation(s) in RCA: 85] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The polypeptide chain of the Ca2+-stimulated adenosine triphosphatase from sarcoplasmic reticulum has a molecular weight of 119 000+/-6500 on the basis of sedimentation equilibrium measurements in sodium dodecyl sulfate. The two primary fragments obtained by limited proteolysis each have within experimental error the same molecular weight, corresponding to one-half the molecular weight of the whole chain. Both fragments are eqaully resistant to complete denaturation by guanidine hydrochloride, a property characteristic of many intrinsic membrane proteins. This suggests that the native enzyme has two membrane-embedded halves, with an externally accessible link between them.
Collapse
|
36
|
Cormier JM, Daumet P, Maire M. [Complex cervico-facial arteriovenous vascular dysplasia treated under circulatory arrest]. Chirurgie 1972; 98:392-6. [PMID: 4538288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
37
|
Maire M. Pemphigus, Dermatitis herpetiformis, Herpes gestationis, Acrodermatitis continua Hallopeau. Dermatology 1954. [DOI: 10.1159/000256742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
38
|
Maire M. Durch wirbellose Tiere erzeugte Hautkrankheiten. Dermatology 1954. [DOI: 10.1159/000256685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
39
|
Maire M. Durch wirbellose Tiere erzeugte Hautkrankheiten. Dermatology 1953. [DOI: 10.1159/000256784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
40
|
|
41
|
Maire M. Durch wirbellose Tiere erzeugte Hautkrankheiten. Dermatology 1951. [DOI: 10.1159/000256998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
42
|
Maire M. Pemphigus, Dermatitis herpetiformis, Impetigo herpetiformis, Acrodermatitis continua Hallopeau. Dermatology 1951. [DOI: 10.1159/000257053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
43
|
Maire M. Pemphigus, Dermatitis herpetiformis, Impetigo herpetiformis, Acrodermatitis Hallopeau. Dermatology 1950. [DOI: 10.1159/000257165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
44
|
Maire M. Durch wirbellose Tiere erzeugte Dermatosen. Dermatology 1950. [DOI: 10.1159/000257211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
45
|
Maire M. Durch wirbellose Tiere erzeugte Dermatosen. Dermatology 1949. [DOI: 10.1159/000257336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
46
|
|
47
|
|
48
|
|
49
|
Maire M. Pemphigus, Dermatitis herpetiformis, Impetigo herpetiformis. Dermatology 1948. [DOI: 10.1159/000256176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|